AVALON GLOBOCARE CORP (ALBT) Stock Price, Forecast & Analysis

NASDAQ:ALBT • US05344R3021

1.48 USD
+0.39 (+35.78%)
At close: Feb 27, 2026
1.44 USD
-0.04 (-2.7%)
After Hours: 2/27/2026, 4:04:06 PM

ALBT Key Statistics, Chart & Performance

Key Statistics
Market Cap6.29M
Revenue(TTM)1.40M
Net Income(TTM)-18.76M
Shares4.25M
Float3.87M
52 Week High11.66
52 Week Low0.42
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-9.75
PEN/A
Fwd PEN/A
Earnings (Next)03-30
IPO2016-02-22
Sector
GICS SectorReal Estate
GICS IndustryReal Estate Management & Development
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
ALBT short term performance overview.The bars show the price performance of ALBT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 -40 60 80

ALBT long term performance overview.The bars show the price performance of ALBT in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALBT is 1.48 USD. In the past month the price increased by 35.17%. In the past year, price decreased by -84.97%.

AVALON GLOBOCARE CORP / ALBT Daily stock chart

ALBT Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to ALBT. When comparing the yearly performance of all stocks, ALBT is a bad performer in the overall market: 96.02% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
ALBT Full Technical Analysis Report

ALBT Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to ALBT. ALBT has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ALBT Full Fundamental Analysis Report

ALBT Financial Highlights

Over the last trailing twelve months ALBT reported a non-GAAP Earnings per Share(EPS) of -9.75. The EPS increased by 50.14% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -205.48%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%96.56%
Sales Q2Q%1.42%
EPS 1Y (TTM)50.14%
Revenue 1Y (TTM)6.65%
ALBT financials

ALBT Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
ALBT Analyst EstimatesALBT Analyst Ratings

ALBT Ownership

Ownership
Inst Owners1.13%
Ins Owners8.87%
Short Float %2.62%
Short Ratio0.36
ALBT Ownership

ALBT Competitors/Peers

The largest stocks on the US markets in the "Real Estate Operating Companies" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
LB LANDBRIDGE CO LLC-A39.495.739B
KW KENNEDY-WILSON HOLDINGS INC N/A1.493B
FRPH FRP HOLDINGS INC N/A458.498M
TCI TRANSCONTINENTAL REALTY INV N/A338.602M
MLP MAUI LAND & PINEAPPLE CO N/A332.422M
SEG SEAPORT ENTERTAINMENT GROUP N/A299.263M
ARL AMERICAN REALTY INVESTORS IN N/A283.432M
OZ BELPOINTE PREP LLC- CLASS A N/A193.566M
SRG SERITAGE GROWTH PROP- A N/A168.96M
MAYS MAYS (J.W.) INC N/A91.95M

About ALBT

Company Profile

ALBT logo image Avalon GloboCare Corp. is a clinical-stage biotechnology company, which engages in the development of immune effector cell therapy and laboratory services. The company is headquartered in Freehold, New Jersey and currently employs 5 full-time employees. The company went IPO on 2016-02-22. The firm operates in two reportable business segments: the real property operating segment and the laboratory testing services segment. Its laboratory services offer a test menu that satisfies the clients' testing needs, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, and it is a one-stop-shop for clinical testing. The firm is currently marketing the KetoAir breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir breathalyzer is a handheld device that allows the user to detect acetone levels in exhaled breath. The acetone level is in concentration units part-per-million (ppm) such that the user knows the real-time ketosis status.

Company Info

AVALON GLOBOCARE CORP

4400 Route 9, Suite 3100

Freehold NEW JERSEY US

Employees: 5

ALBT Company Website

ALBT Investor Relations

Phone: 17327804400

AVALON GLOBOCARE CORP / ALBT FAQ

Can you describe the business of AVALON GLOBOCARE CORP?

Avalon GloboCare Corp. is a clinical-stage biotechnology company, which engages in the development of immune effector cell therapy and laboratory services. The company is headquartered in Freehold, New Jersey and currently employs 5 full-time employees. The company went IPO on 2016-02-22. The firm operates in two reportable business segments: the real property operating segment and the laboratory testing services segment. Its laboratory services offer a test menu that satisfies the clients' testing needs, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, and it is a one-stop-shop for clinical testing. The firm is currently marketing the KetoAir breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir breathalyzer is a handheld device that allows the user to detect acetone levels in exhaled breath. The acetone level is in concentration units part-per-million (ppm) such that the user knows the real-time ketosis status.


What is the current price of ALBT stock?

The current stock price of ALBT is 1.48 USD. The price increased by 35.78% in the last trading session.


Does ALBT stock pay dividends?

ALBT does not pay a dividend.


What is the ChartMill rating of AVALON GLOBOCARE CORP stock?

ALBT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Which stock exchange lists ALBT stock?

ALBT stock is listed on the Nasdaq exchange.


Is AVALON GLOBOCARE CORP (ALBT) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALBT.


Can you provide the ownership details for ALBT stock?

You can find the ownership structure of AVALON GLOBOCARE CORP (ALBT) on the Ownership tab.